Cambridge Institute for Medical Research

Professor Tony Green

Professor Tony Green

Home | Research Profile | Key Publications

Selected publications since 2005:

Tijssen MR, Cvejic A, Joshi A, Hannah RL, Ferreira R, Forrai A, Bellissino DC, Oram SH, Smethurst PA, Wilson NK, Wang X, Ottersbach K, Stemple DL, Green AR, Ouwehand WH, Gottgens B.  Identification of hematopoietic regulators through genome-wide analysis of simultaneous GATA1, GATA2, RUNX1, FLI1 and SCL binding in megakaryocytes.  Developmental Cell, 20(5): 597-609, 2011.

Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin M-L, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ.  Massive genomic rearrangement acquired in a single catastrophic event during cancer development.  Cell, 144(1): 27-40, 2011.

Griffiths DS, Li J, Dawson MA, Trotter M, Cheng YH, Smith A, Mansfield W, Liu P, Kouzarides T, Nichols J, Bannister A, Green AR and Göttgens B.  LIF independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.  Nature Cell Biology, 13(1): 13-21, 2011.

Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, Bench A, Erber W, Green AR, Huntly BJP.  Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.  Blood, 118(1): 177-181, 2011

Anand S, Stedham F, Gudgin E, Campbell P, Beer P, Green AR, Hunty BJP. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.  Blood, 118(6): 1610-1621, 2011.

Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS, Hasselbalch HC, Vannucchi AM, Möller P, Döhner K, and Green AR.  Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms.  Haematologica, 95(12): 2153-2156, 2010.

Gottgens B, Ferreira R, Sanchez MJ, Ishibashi S, Li J, Spensberger D, Lefevre P, Ottersbach K, Chapman M, Kinston S, Knezevic K, Hoogenkamp M, Follows GA, Bonifer C, Amaya E, Green AR.  Cis-regulatory remodeling of the SCL locus during vertebrate evolution.  Molecular and Cellular Biology.  30(24) 5741-5751, 2010.

Chen E, Beer PA, Godfrey AL, Ortmann CA, Li J, Costa-Pereira AP, Ingle CE, Dermitzakis ET, Campbell PJ, and Green AR.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.  Cancer Cell, 18(5): 524-535, 2010.

Beer PA, Green AR.  Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia.  Blood, 116(6): 1013-1014, 2010.

Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, Percy MJ, McMullin MF, Scott LM, Tapper W, Silver RT, Oscier D, Harrison CN, Grallert H, Kisialiou A, Strike P, Chase AJ, Green AR and Cross NCP.  The JAK2 46/1 haplotype predisposes to both MPL and JAK2 mutated myeloproliferative neoplasms.  Blood, 115(22): 4517-4523, 2010.

Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, Chen E, Forrai A, Scott LM, Ferreira R, Campbell PJ, Watson SP, Liu P, Erber WN, Huntly BJ, Ottersbach K, Green AR.  JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.  Blood, 116(9): 1528-1538, 2010.

Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kušec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR.   Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood, 115(14): 2891-2900, 2010

Dawson MA†, Bannister AJ†, Gottgens B, Foster SD, Bartke T, Green AR*, Kouzarides T* (*joint senior authors; †joint first author).  JAK2 phosphorylates histone H3Y41 and excludes HP1a  from chromatin.  Nature, 461(7265): 819-822, 2009.

Beer PA, Jones AV, Bench BJ, Goday-Fernandez A, Boyd EM, Vaghela KJ, Erber WN, Odeh B, Wright C, McMullin MF, Cullis J, Huntly BJP, Harrison CN, Cross NCP, Green AR.  Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.  British Journal of Haematology.  British Journal of Haematology 144: 904-908 2009.

Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN, Green AR, Johnston JA.  SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.  Haematologica, 94(4); 576-580, 2009.

Wood AD, Chen E, Donaldson IJ, Hattangadi S, Burke KA, Dawson MA, Miranda-Saavedra D, Lodish HF, Green AR, Gottgens B.  ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signalling.  Blood, 114: 1820-1830, 2009.

Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. . J Clin Oncol, 27: 2991-2999 2009.

Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJP, Green AR*, Alexander DR*.  Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.  (*joint senior authors).  N. Engl J Med, 359(26): 2778-2789, 2008.

Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech Arava, Shocaht C, Cazzaniga G, Biondi A, Basso G, Cario G, Schrappe M, Stanulla M, Strehl S, Haas OA, Mann G, Binder V, Borkhardt A, Kempski H, Trka J, Bielorei B, Avigad S, Stark B, Smith O, Dastugue N, Bourquin J-P, Tal NB, Green AR, Izraeli S.  Mutations of JAK in acute lymphoblastic leukaemias associated with down’s syndrome.  Lancet, 372: 1448-1450, 2008.

Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.  Blood, 112: 141-149, 2008.

Smith AM, Sanchez MJ, Follows GA, Kinston S, Donaldson IJ, Green AR, Göttgens B.  A novel mode of enhancer evolution: The Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity. Genome Research 18: 1422-1432, 2008.

Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ.  Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.  Blood, 111: 60-70, 2008.

Ogilvy S, Ferreira R, Piltz SG, Bowen JM, Göttgens B, Green AR.  The SCL +40 enhancer targets midbrain together with primitive and definitive hematopoiesis and is regulated by SCL and GATA proteins.  Mol Cell Biol, 27: 7206-7219, 2007.

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.  N Engl J Med 356: 459-468, 2007.

Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR.  DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol, 5: 0039-0053, 2007.

Campbell PJ, Green AR.  The myeloproliferative disorders.  N Engl J Med 23: 2452-2466, 2006.

Scott LM, Scott MA, Campbell PJ and Green AR. Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435-2437, 2006.

Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN and Green AR.  Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 108: 3548-3555, 2006.

Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès M-C, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian J-J, Viallard J-F, Brière J, Harrison C, Green AR, Reilly JT.  V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.  Blood 107: 2098-2100, 2006.

Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, Gottgens B.  Endoglin expression in the endothelium is regulated by Fli-1, Erg and Elf-1 acting on the promoter and a –8kb enhancer.  Blood 107: 4737-4745, 2006.

Pimanda JE, Silberstein L, Dominici M, Dekel B, Bowen M,Oldham S, Kallianpur A, Brandt SJ, Tannahill D, Gottgens B, Green AR.  Transcriptional link between blood and bone: the stem cell leukemia gene and its +19 stem cell enhancer are active in bone cells.  Mol Cell Biol 26: 2615-2625, 2006.

Delabesse E, Ogilvy S, Chapman MA, Piltz SG, Gottgens B & Green AR. Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo.  Mol Cell Biol 25: 5215-5225, 2005.

Donaldson IJ, Chapman M, Kinson S, Landry J-R, Knezevic K, Piltz S, Buckley N, Green AR & Göttgens B.  Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development.  Human Mol Genet 14: 1-7, 2005

Eguchi M, Eguchi-Ishimae M, Green AR, Enver T & Greaves M.  Directing oncogenic fusion genes into stem cells via an SCL enhancer.  Proc Natl Acad Sci (USA) 102: 1133-1138, 2005.

Scott LM, Campbell J, E. Baxter J, Todd A, Stephens P, Edkins S, Wooster R, Stratton MR, Futreal PA, Green AR. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.  Blood 106: 2920-2921, 2005.

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.  Lancet 366: 1945-1953, 2005.

Harrison CN, Campbell PJ, Buck G,Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg, AP Revell P, Woodcock BE & Green AR.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.  N Engl J Med 353: 33-45, 2005.

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott M, Erber WN, Cancer Genome Project, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.  Lancet 365: 1054-1061, 2005.